The latest update is out from Tectonic Therapeutic (TECX).
Tectonic Therapeutic, Inc. has refreshed its corporate presentation for discussions with investors and analysts, accessible on its investor website. The company also announced its upcoming Phase 2 clinical trial of TX45, aimed at treating Group 2 Pulmonary Hypertension in heart failure patients, which is scheduled to commence in the latter half of 2024 with an international scope. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could affect outcomes and the company’s financial position.
For a thorough assessment of TECX stock, go to TipRanks’ Stock Analysis page.
